Recombinant Human Growth Hormone is named as a drug or biological intervention in 4 clinical trials in our China trial register, 3 of which are recruiting. Lead sponsors include Xiamen Amoytop Biotech Co., Ltd. (2) and Changchun GeneScience Pharmaceutical Co., Ltd. (2). Registered phases: Phase 3, Phase 1/2 and Phase 1. Conditions studied include Idiopathic Short Stature; Small for Gestational Age; Safety.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06927310 | The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature (ClinicalTrials.gov ↗) Idiopathic Short Stature |
Phase 3 | Recruiting |
| NCT07309562 | The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age (ClinicalTrials.gov ↗) Small for Gestational Age |
Phase 3 | Recruiting |
| NCT07016802 | A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) (ClinicalTrials.gov ↗) Safety, Tolerability, Adult Growth Hormone Deficiency |
Phase 1 | Recruiting |
| NCT07450053 | A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS) (ClinicalTrials.gov ↗) Idiopathic Short Stature |
Phase 1/2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Idiopathic Short Stature | 2 |
| Small for Gestational Age | 1 |
| Safety | 1 |
| Tolerability | 1 |
| Adult Growth Hormone Deficiency | 1 |
| Lead sponsor | Trials |
|---|---|
| Xiamen Amoytop Biotech Co., Ltd. | 2 |
| Changchun GeneScience Pharmaceutical Co., Ltd. | 2 |
| Register | Recombinant Human Growth Hormone trials |
|---|---|
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Recombinant Human Growth Hormone works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Recombinant Human Growth Hormone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.